SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Citi: CSL Injectafer black box label warning likely limited impact

Citi says the FDA-approved revised Injectafer labeling—adding a black box warning about low blood phosphate risk—is unlikely to change much for CSL.

CSL

Citi said the addition of a black box warning to the label of CSL's Injectafer is unlikely to have a big impact. The Food and Drug Administration approved revised labeling for the iron replacement medicine to warn of the risk of low levels of phosphate in the blood.

Related stories